Rachael Safyan
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Background: Stromal hyaluronic acid (HA) poses a physical barrier and protects tumor cells from immune surveillance. Stroma targeting with pegylated human recombinant PH20 hyaluronidase (PEGPH20) demonstrated improved infiltration of cytotoxic T-lymphocytes and delivery of chemotherapy and PD1/PD-L1 antibodies in tumor models. This multicenter phase II study of PEGPH20 plus pembrolizumab evaluated the efficacy, safety and immune and stromal biomarkers in patients with HA-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA). Patients and Methods: Patients were treated with PEGPH20 3 µg/kg IV weekly and pembrolizumab 200 mg IV in 3-week cycles. Tumor and blood samples were collected at baseline and on-study for biomarker analyses. Results: Between May and November 2019, 38 patients were screened and 8 treated, with median age 68 years (range 60–73) and median two (range 1–4) prior therapies. The study was closed to accrual early by pharmaceutical sponsor. Treatment was well tolerated, with expected grade 1/2 musculoskeletal toxicities. Best response was stable disease in 2 of 7 evaluable patients (29%). Median overall and progression-free survival were 7.2 months (95% CI 1.2–11.8) and 1.5 months (95% CI 0.9–4.4), respectively. Prolonged survival (range 10.2–27.6 months) occurred in patients treated with subsequent chemotherapy. Higher baseline tumor T cell receptor (TCR) clonality correlated with longer survival. Conclusions: Pembrolizumab with PEGPH20 was safe but did not have significant efficacy in refractory HA-high metastatic PDA.
Year:
2026
Background: The epidermal growth factor receptor (EGFR) is overactive in many tumors. This phase I trial evaluated the safety and preliminary efficacy of afatinib plus capecitabine in refractory pancreatic ductal adenocarcinoma (PDA), biliary tract cancers (BTC), and other solid tumors. Patients and Methods: The phase Ia study had a 3 + 3 design with capecitabine 1000 mg/m2 twice daily on days 1–14 and afatinib 20 mg, 30 mg, or 40 mg daily in 21-day cycles. In phase Ib, 15 patients, each with PDA and BTC, were treated at maximum tolerated dose (MTD). Results: A total of 41 patients were enrolled. No dose-limiting toxicities were observed, and the MTD was 40 mg afatinib plus capecitabine. Among 36 response-evaluable patients, one had a partial response (3%), and eight (22%) had stable disease. Median progression-free survival (PFS) was 1.9 months (95% CI 1.0, 2.0) for PDA and 1.9 months (95% CI 1.6, 3.4) for BTC. Median overall survival (OS) was 3.2 months (95% CI 2.0, 5.8) for PDA, and 4.6 months (95% CI 1.9, 6.1) for BTC. Median OS was 5.8 months (95% CI 2.0, 9.6) for KRASWT PDA, and 5.0 months (95% CI 1.6, 6.1) for KRASWT BTC, vs. 3.9 months (95% CI 1.9, 5.8) for KRASMUT PDA and 3.1 months (95% CI 1.0, 22.8) for KRASMUT BTC, respectively. Conclusions: Afatinib plus capecitabine is tolerable but does not have clinically meaningful efficacy in refractory PDA/BTC. Future studies should test novel anti-EGFR/HER2 therapies in KRASWT cancers further selected with a comprehensive molecular profile.
Year:
2025
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.
Year:
2025
Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.
Year:
2025
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.
Year:
2025
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).
Year:
2025
Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination GnP first-line chemotherapy. B) GATA6 status does not predict overall survival when patients receive first line mFFX chemotherapy.
Year:
2025
Supplementary Figure S3. Consort Diagram and Mixed Populations. A) Consort diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. For treatment response analyses, patients were further subdivided by type of chemotherapy received, and neoadjuvant-treated samples were considered separately (n = 51). B) Mixed (HMGA2+ GATA6+) and double negative (HMGA2- GATA6-) populations show intermediate survival between basal and classical tumors.
Year:
2025
Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining CK5 and GATA6 IHC does not predict overall survival. B) CK17 high, GATA6 low tumors display improved survival compared to CK17 low, GATA6 high tumors. C) Kaplan-Meier survival curves for CK5 positive and negative tumors treated with first-line gemcitabine chemotherapy. D) Kaplan-Meier survival curves for CK17 positive and negative tumors treated with first-line gemcitabine chemotherapy. E) CK5 status does not predict time to recurrence. F) CK17 positive tumors show longer time to recurrence than CK17 negative tumors, the opposite phenotype expected from the basal subtype.
Year:
2025
Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution for TMA and Ochsner cohorts. B) Race distribution for TMA and Ochsner cohorts. C) Proportions of disease by stage (left) and resulting survival (right) predicts survival in TMA cohort (AJCC 8th edition).
Year:
2025
Year:
2025
Collaborators (12)
Howard Crawford
Professor
University of Michigan
Stacey Cohen
Fred Hutchinson Cancer Research Center
David Zhen
Associate Professor
Montefiore Medical Center
Sita Kugel
Professor
Fred Hutch Cancer Center
David G. DeNardo
Professor of Medicine
Washington University School of Medicine
Sunil Hingorani
Fred Hutchinson Cancer Research Center
E. Gabriela Chiorean
Professor of Medicine
University of Washington
Kiran Vij
Associate Professor
Washington University in St. Louis
Ryan C. Fields
University of Rochester
Eric Konnick
Associate Professor
University of Washington
Andrew Coveler
Fred Hutchinson Cancer Research Center
Nina Steele
Assistant Professor
University of Cincinnati
Make your next move.
Prepare your application
Review drafts before you send them.